Infanrix Penta

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
10-07-2013
Summary of Product characteristics Summary of Product characteristics (SPC)
10-07-2013
Public Assessment Report Public Assessment Report (PAR)
10-07-2013

Active ingredient:

Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain)), hepatitis B surface antigen

Available from:

GlaxoSmithKline Biologicals S.A.

ATC code:

J07CA12

INN (International Name):

diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed)

Therapeutic group:

Vaccines

Therapeutic area:

Hepatitis B; Tetanus; Immunization; Whooping Cough; Poliomyelitis; Diphtheria

Therapeutic indications:

Infanrix Penta is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B and poliomyelitis.

Product summary:

Revision: 13

Authorization status:

Withdrawn

Authorization date:

2000-10-23

Patient Information leaflet

                                Medicinal product no longer authorised
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1
Medicinal product no longer authorised
1.
NAME OF THE MEDICINAL PRODUCT
Infanrix Penta, Suspension for injection
Diphtheria (D), tetanus (T), pertussis (acellular, com
ponent) (Pa), hepatitis B (rDNA) (HBV),
poliom
yelitis (inactivated) (IPV) vaccine (adsorbed)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (0.5 ml) contains:
Diphtheria toxoid
1
not less than 30 IU
Tetanus toxoid
1
not less than 40 IU
_Bordetella pertussis_
antigens
Pertussis toxoid
1
25 micrograms
Filamentous Haemagglutinin
1
25 micrograms
Pertactin
1
8 micrograms
Hepatitis B surface antigen
2,3
10 micrograms
Poliovirus (inactivated)
type 1 (Mahoney strain)
4
40 D-antigen unit
type 2 (MEF-1 strain)
4
8 D-antigen unit
type 3 (Saukett strain)
4
32 D-antigen unit
1
adsorbed on aluminium hydroxide, hydrated (Al(OH)3)
0.5 milligrams Al
3+
2
produced in yeast cells (
_Saccharomyces cerevisiae_
) by recombinant DNA technology
3
adsorbed on aluminium phosphate (AlPO4)
0.2 milligrams Al
3+
4
propagated in VERO cells
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection
Infanrix Penta is a turbid white suspension.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Infanrix Penta is indicated for primary and booster vaccination of
infants against diphtheria, tetanus,
pertussis, hepatitis B and poliom
y
elitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
Primary vaccination:
The primary vaccination schedule consists of three doses of 0.5 m
l (such as 2, 3, 4 months; 3, 4, 5
months; 2, 4, 6 months) or two doses (such as 3, 5 months). There
should be an interval of at least 1
month between doses.
2
Medicinal product no longer authorised
The Expanded Program on Immunisation schedule (at 6, 10, 14 weeks of
age) may only be used if a
dose of hepatitis B vaccine has been given at birth.
Locally established immunoprophylactic measures against hepatitis B
should be m
a
intained.
Where a dose of hepatitis B vaccine is given at 
                                
                                Read the complete document

Summary of Product characteristics

                                Medicinal product no longer authorised
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
1
Medicinal product no longer authorised
1.
NAME OF THE MEDICINAL PRODUCT
Infanrix Penta, Suspension for injection
Diphtheria (D), tetanus (T), pertussis (acellular, com
ponent) (Pa), hepatitis B (rDNA) (HBV),
poliom
yelitis (inactivated) (IPV) vaccine (adsorbed)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
1 dose (0.5 ml) contains:
Diphtheria toxoid
1
not less than 30 IU
Tetanus toxoid
1
not less than 40 IU
_Bordetella pertussis_
antigens
Pertussis toxoid
1
25 micrograms
Filamentous Haemagglutinin
1
25 micrograms
Pertactin
1
8 micrograms
Hepatitis B surface antigen
2,3
10 micrograms
Poliovirus (inactivated)
type 1 (Mahoney strain)
4
40 D-antigen unit
type 2 (MEF-1 strain)
4
8 D-antigen unit
type 3 (Saukett strain)
4
32 D-antigen unit
1
adsorbed on aluminium hydroxide, hydrated (Al(OH)3)
0.5 milligrams Al
3+
2
produced in yeast cells (
_Saccharomyces cerevisiae_
) by recombinant DNA technology
3
adsorbed on aluminium phosphate (AlPO4)
0.2 milligrams Al
3+
4
propagated in VERO cells
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Suspension for injection
Infanrix Penta is a turbid white suspension.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Infanrix Penta is indicated for primary and booster vaccination of
infants against diphtheria, tetanus,
pertussis, hepatitis B and poliom
y
elitis.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
_Posology _
Primary vaccination:
The primary vaccination schedule consists of three doses of 0.5 m
l (such as 2, 3, 4 months; 3, 4, 5
months; 2, 4, 6 months) or two doses (such as 3, 5 months). There
should be an interval of at least 1
month between doses.
2
Medicinal product no longer authorised
The Expanded Program on Immunisation schedule (at 6, 10, 14 weeks of
age) may only be used if a
dose of hepatitis B vaccine has been given at birth.
Locally established immunoprophylactic measures against hepatitis B
should be m
a
intained.
Where a dose of hepatitis B vaccine is given at 
                                
                                Read the complete document

Similar products

Active ingredient Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain)), hepatitis B surface antigen

Diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain)), hepatitis B surface antigen

ATC code J07CA12

J07CA12

Marketed by GlaxoSmithKline Biologicals S.A.

GlaxoSmithKline Biologicals S.A.

INN (International Name) diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed)

diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed)

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-07-2013
Public Assessment Report Public Assessment Report Bulgarian 10-07-2013
Patient Information leaflet Patient Information leaflet Spanish 10-07-2013
Summary of Product characteristics Summary of Product characteristics Spanish 10-07-2013
Public Assessment Report Public Assessment Report Spanish 10-07-2013
Patient Information leaflet Patient Information leaflet Czech 10-07-2013
Summary of Product characteristics Summary of Product characteristics Czech 10-07-2013
Public Assessment Report Public Assessment Report Czech 10-07-2013
Patient Information leaflet Patient Information leaflet Danish 10-07-2013
Summary of Product characteristics Summary of Product characteristics Danish 10-07-2013
Public Assessment Report Public Assessment Report Danish 10-07-2013
Patient Information leaflet Patient Information leaflet German 10-07-2013
Summary of Product characteristics Summary of Product characteristics German 10-07-2013
Public Assessment Report Public Assessment Report German 10-07-2013
Patient Information leaflet Patient Information leaflet Estonian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Estonian 10-07-2013
Public Assessment Report Public Assessment Report Estonian 10-07-2013
Patient Information leaflet Patient Information leaflet Greek 10-07-2013
Summary of Product characteristics Summary of Product characteristics Greek 10-07-2013
Public Assessment Report Public Assessment Report Greek 10-07-2013
Patient Information leaflet Patient Information leaflet French 10-07-2013
Summary of Product characteristics Summary of Product characteristics French 10-07-2013
Public Assessment Report Public Assessment Report French 10-07-2013
Patient Information leaflet Patient Information leaflet Italian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Italian 10-07-2013
Public Assessment Report Public Assessment Report Italian 10-07-2013
Patient Information leaflet Patient Information leaflet Latvian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Latvian 10-07-2013
Public Assessment Report Public Assessment Report Latvian 10-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-07-2013
Public Assessment Report Public Assessment Report Lithuanian 10-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Hungarian 10-07-2013
Public Assessment Report Public Assessment Report Hungarian 10-07-2013
Patient Information leaflet Patient Information leaflet Maltese 10-07-2013
Summary of Product characteristics Summary of Product characteristics Maltese 10-07-2013
Public Assessment Report Public Assessment Report Maltese 10-07-2013
Patient Information leaflet Patient Information leaflet Dutch 10-07-2013
Summary of Product characteristics Summary of Product characteristics Dutch 10-07-2013
Public Assessment Report Public Assessment Report Dutch 10-07-2013
Patient Information leaflet Patient Information leaflet Polish 10-07-2013
Summary of Product characteristics Summary of Product characteristics Polish 10-07-2013
Public Assessment Report Public Assessment Report Polish 10-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 10-07-2013
Summary of Product characteristics Summary of Product characteristics Portuguese 10-07-2013
Public Assessment Report Public Assessment Report Portuguese 10-07-2013
Patient Information leaflet Patient Information leaflet Romanian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Romanian 10-07-2013
Public Assessment Report Public Assessment Report Romanian 10-07-2013
Patient Information leaflet Patient Information leaflet Slovak 10-07-2013
Summary of Product characteristics Summary of Product characteristics Slovak 10-07-2013
Public Assessment Report Public Assessment Report Slovak 10-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Slovenian 10-07-2013
Public Assessment Report Public Assessment Report Slovenian 10-07-2013
Patient Information leaflet Patient Information leaflet Finnish 10-07-2013
Summary of Product characteristics Summary of Product characteristics Finnish 10-07-2013
Public Assessment Report Public Assessment Report Finnish 10-07-2013
Patient Information leaflet Patient Information leaflet Swedish 10-07-2013
Summary of Product characteristics Summary of Product characteristics Swedish 10-07-2013
Public Assessment Report Public Assessment Report Swedish 10-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 10-07-2013
Summary of Product characteristics Summary of Product characteristics Norwegian 10-07-2013
Patient Information leaflet Patient Information leaflet Icelandic 10-07-2013
Summary of Product characteristics Summary of Product characteristics Icelandic 10-07-2013

Search alerts related to this product

Alerts Infanrix Penta Diphtheria toxoid, tetanus Bordetella pertussis hepatitis poliomyelitis vaccine

Infanrix Penta Diphtheria toxoid, tetanus Bordetella pertussis hepatitis poliomyelitis vaccine

View documents history

Documents history Documents history

Infanrix Penta